Consolidative radiotherapy in oligometastatic and oligoprogressive NSCLC: A systematic review
Authors:
Open Access
- 9 March 2025
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 210, 104676
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Circulating tumor DNA kinetics: A future tool for radiation therapy personalization in lung cancer?The Journal of Liquid Biopsy, 2024
- Stereotactic Ablative Radiotherapy for Oligo-Progressive Cancers: Results of the Randomized Phase II STOP TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2023
- Palliative Radiation for Advanced Central Lung Tumors With Intentional Avoidance of the Esophagus (PROACTIVE)JAMA Oncology, 2022
- Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 studyLung Cancer, 2021
- ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKILung Cancer, 2020
- Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung CancerJAMA Oncology, 2019
- Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung CancerJAMA Oncology, 2019
- Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Ultracentral Thorax Malignancies: Results of a Phase 1 TrialAdvances in Radiation Oncology, 2019
- Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung CancerJAMA Oncology, 2017
- Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC)Lung Cancer, 2008